Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 136

1.

18F-FPPRGD2 PET/CT in patients with metastatic renal cell cancer.

Toriihara A, Duan H, Thompson HM, Park S, Hatami N, Baratto L, Fan AC, Iagaru A.

Eur J Nucl Med Mol Imaging. 2019 Mar 8. doi: 10.1007/s00259-019-04295-7. [Epub ahead of print]

PMID:
30850872
2.

Serial Cardiac FDG-PET for the Diagnosis and Therapeutic Guidance of Patients with Cardiac Sarcoidosis.

Ning N, Guo HH, Iagaru A, Mittra E, Fowler M, Witteles R.

J Card Fail. 2019 Feb 27. pii: S1071-9164(19)30201-5. doi: 10.1016/j.cardfail.2019.02.018. [Epub ahead of print]

PMID:
30825644
3.

Multimodality Hyperpolarized C-13 MRS/PET/Multiparametric MR Imaging for Detection and Image-Guided Biopsy of Prostate Cancer: First Experience in a Canine Prostate Cancer Model.

Bachawal SV, Park JM, Valluru KS, Loft MD, Felt SA, Vilches-Moure JG, Saenz YF, Daniel B, Iagaru A, Sonn G, Cheng Z, Spielman DM, Willmann JK.

Mol Imaging Biol. 2019 Feb 21. doi: 10.1007/s11307-018-1235-6. [Epub ahead of print]

PMID:
30793241
4.

NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018.

Haddad RI, Nasr C, Bischoff L, Busaidy NL, Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Goldner W, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, McIver B, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Sippel R, Smallridge RC, Sturgeon C, Wang TN, Wirth LJ, Wong RJ, Johnson-Chilla A, Hoffmann KG, Gurski LA.

J Natl Compr Canc Netw. 2018 Dec;16(12):1429-1440. doi: 10.6004/jnccn.2018.0089.

PMID:
30545990
5.

Diagnostic 123I Whole Body Scan Prior to Ablation of Thyroid Remnant in Patients With Papillary Thyroid Cancer: Implications for Clinical Management.

Song H, Mosci C, Akatsu H, Basina M, Dosiou C, Iagaru A.

Clin Nucl Med. 2018 Oct;43(10):705-709. doi: 10.1097/RLU.0000000000002246.

PMID:
30153149
6.

Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle.

Bartelink IH, Jones EF, Shahidi-Latham SK, Lee PRE, Zheng Y, Vicini P, van 't Veer L, Wolf D, Iagaru A, Kroetz DL, Prideaux B, Cilliers C, Thurber GM, Wimana Z, Gebhart G.

Clin Pharmacol Ther. 2018 Aug 14. doi: 10.1002/cpt.1211. [Epub ahead of print] Review.

PMID:
30107040
7.

Nuclear Medicine Imaging Techniques for Detection of Skeletal Metastases in Breast Cancer.

Iagaru A, Minamimoto R.

PET Clin. 2018 Jul;13(3):383-393. doi: 10.1016/j.cpet.2018.02.002. Review.

PMID:
30100077
8.

Combined 68Ga-NOTA-PRGD2 and 18F-FDG PET/CT Can Discriminate Uncommon Meningioma Mimicking High-Grade Glioma.

Li D, Zhang J, Ji N, Zhao X, Zheng K, Qiao Z, Li F, Lang L, Iagaru A, Niu G, Zhu Z, Chen X.

Clin Nucl Med. 2018 Sep;43(9):648-654. doi: 10.1097/RLU.0000000000002233.

PMID:
30052597
9.

18F-florbetaben whole-body PET/MRI for evaluation of systemic amyloid deposition.

Baratto L, Park SY, Hatami N, Gulaka P, Vasanawala S, Yohannan TK, Herfkens R, Witteles R, Iagaru A.

EJNMMI Res. 2018 Jul 24;8(1):66. doi: 10.1186/s13550-018-0425-1.

10.

Clinical Evaluation of 68Ga-PSMA-II and 68Ga-RM2 PET Images Reconstructed With an Improved Scatter Correction Algorithm.

Wangerin KA, Baratto L, Khalighi MM, Hope TA, Gulaka PK, Deller TW, Iagaru AH.

AJR Am J Roentgenol. 2018 Sep;211(3):655-660. doi: 10.2214/AJR.17.19356. Epub 2018 Jun 6.

PMID:
29873506
11.

Gallium 68 PSMA-11 PET/MR Imaging in Patients with Intermediate- or High-Risk Prostate Cancer.

Park SY, Zacharias C, Harrison C, Fan RE, Kunder C, Hatami N, Giesel F, Ghanouni P, Daniel B, Loening AM, Sonn GA, Iagaru A.

Radiology. 2018 Aug;288(2):495-505. doi: 10.1148/radiol.2018172232. Epub 2018 May 22.

PMID:
29786490
12.

Standard OSEM vs. regularized PET image reconstruction: qualitative and quantitative comparison using phantom data and various clinical radiopharmaceuticals.

Lantos J, Mittra ES, Levin CS, Iagaru A.

Am J Nucl Med Mol Imaging. 2018 Apr 25;8(2):110-118. eCollection 2018.

13.

Embrace Progress.

Bradley KM, McGowan DR, Gleeson FV, Johnson GB, Young JR, Levin CS, Davidzon GA, Iagaru AH.

J Nucl Med. 2018 Jul;59(7):1169. doi: 10.2967/jnumed.118.212761. Epub 2018 Apr 26. No abstract available.

PMID:
29700130
14.

Initial experience with a SiPM-based PET/CT scanner: influence of acquisition time on image quality.

Sonni I, Baratto L, Park S, Hatami N, Srinivas S, Davidzon G, Gambhir SS, Iagaru A.

EJNMMI Phys. 2018 Apr 18;5(1):9. doi: 10.1186/s40658-018-0207-x.

15.

Anaplastic Thyroid Cancer With Extensive Skeletal Muscle Metastases on 18F-FDG PET/CT.

Yurkiewicz IR, Ganjoo KN, Iagaru A.

Clin Nucl Med. 2018 Apr;43(4):e113-e114. doi: 10.1097/RLU.0000000000001968.

PMID:
29356736
16.

Prostate Cancer Theranostics Targeting Gastrin-Releasing Peptide Receptors.

Baratto L, Jadvar H, Iagaru A.

Mol Imaging Biol. 2018 Aug;20(4):501-509. doi: 10.1007/s11307-017-1151-1. Review.

PMID:
29256046
17.

Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program.

Sartor O, Vogelzang NJ, Sweeney C, Fernandez DC, Almeida F, Iagaru A, Brown A Jr, Smith MR, Agrawal M, Dicker AP, Garcia JA, Lutzky J, Wong YN, Petrenciuc O, Gratt J, Shore ND, Morris MJ; U.S. Expanded Access Program Investigators.

Oncologist. 2018 Feb;23(2):193-202. doi: 10.1634/theoncologist.2017-0413. Epub 2017 Nov 28.

18.

Prospective Evaluation of 68Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer and Negative Findings on Conventional Imaging.

Minamimoto R, Sonni I, Hancock S, Vasanawala S, Loening A, Gambhir SS, Iagaru A.

J Nucl Med. 2018 May;59(5):803-808. doi: 10.2967/jnumed.117.197624. Epub 2017 Oct 30.

PMID:
29084827
19.

Comparison Between Different PET and CT-Based Imaging Interpretation Criteria at Interim Imaging in Patients With Diffuse Large B-Cell Lymphoma.

Baratto L, Davidzon GA, Moghbel M, Hatami N, Iagaru A, Mittra ES.

Clin Nucl Med. 2018 Jan;43(1):1-8. doi: 10.1097/RLU.0000000000001880.

PMID:
29076913
20.

Carcinoid Syndrome Complicating a Pancreatic Neuroendocrine Tumor: A Case Report.

Gerson JN, Witteles RM, Chang DT, Beygui RE, Iagaru AH, Kunz PL.

Pancreas. 2017 Nov/Dec;46(10):1381-1385. doi: 10.1097/MPA.0000000000000932.

PMID:
29040196
21.

Relative value of three whole-body MR approaches for PET-MR, including gadofosveset-enhanced MR, in comparison to PET-CT.

Obara P, Loening A, Taviani V, Iagaru A, Hargreaves BA, Vasanawala S.

Clin Imaging. 2018 Mar - Apr;48:62-68. doi: 10.1016/j.clinimag.2017.09.016. Epub 2017 Sep 29.

PMID:
29031209
22.

Appropriate Use Criteria for 18F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease.

Jadvar H, Colletti PM, Delgado-Bolton R, Esposito G, Krause BJ, Iagaru AH, Nadel H, Quinn DI, Rohren E, Subramaniam RM, Zukotynski K, Kauffman J, Ahuja S, Griffeth L.

J Nucl Med. 2017 Dec;58(12):2026-2037. doi: 10.2967/jnumed.117.197988. Epub 2017 Oct 12. No abstract available.

23.

Will GRPR Compete with PSMA as a Target in Prostate Cancer?

Iagaru A.

J Nucl Med. 2017 Dec;58(12):1883-1884. doi: 10.2967/jnumed.117.198192. Epub 2017 Sep 28. No abstract available.

24.

Intragastric Meal Distribution During Gastric Emptying Scintigraphy for Assessment of Fundic Accommodation: Correlation with Symptoms of Gastroparesis.

Orthey P, Yu D, Van Natta ML, Ramsey FV, Diaz JR, Bennett PA, Iagaru AH, Fragomeni RS, McCallum RW, Sarosiek I, Hasler WL, Farrugia G, Grover M, Koch KL, Nguyen L, Snape WJ, Abell TL, Pasricha PJ, Tonascia J, Hamilton F, Parkman HP, Maurer AH; NIH Gastroparesis Consortium.

J Nucl Med. 2018 Apr;59(4):691-697. doi: 10.2967/jnumed.117.197053. Epub 2017 Sep 28.

25.

Semiquantitative Assessment of 18F-FDG Uptake in the Normal Skeleton: Comparison Between PET/CT and Time-of-Flight Simultaneous PET/MRI.

Minamimoto R, Xu G, Jamali M, Holley D, Barkhodari A, Zaharchuk G, Iagaru A.

AJR Am J Roentgenol. 2017 Nov;209(5):1136-1142. doi: 10.2214/AJR.17.18044. Epub 2017 Aug 4.

PMID:
28777652
26.

68Ga-PSMA-11 PET/CT in Newly Diagnosed Carcinoma of the Prostate: Correlation of Intraprostatic PSMA Uptake with Several Clinical Parameters.

Koerber SA, Utzinger MT, Kratochwil C, Kesch C, Haefner MF, Katayama S, Mier W, Iagaru AH, Herfarth K, Haberkorn U, Debus J, Giesel FL.

J Nucl Med. 2017 Dec;58(12):1943-1948. doi: 10.2967/jnumed.117.190314. Epub 2017 Jun 15.

27.

18F-FDG silicon photomultiplier PET/CT: A pilot study comparing semi-quantitative measurements with standard PET/CT.

Baratto L, Park SY, Hatami N, Davidzon G, Srinivas S, Gambhir SS, Iagaru A.

PLoS One. 2017 Jun 5;12(6):e0178936. doi: 10.1371/journal.pone.0178936. eCollection 2017.

28.

ACR and SNMMI Joint Credentialing Statement for PET/MRI of the Body.

Subramaniam RM, Jadvar H, Colletti PM, Guimaraes A, Gullapali R, Iagaru AH, McConathy J, Meltzer CC, Nadel H, Noto RB, Packard AB, Rohren EM, Oates ME.

J Nucl Med. 2017 Jul;58(7):1174-1176. doi: 10.2967/jnumed.117.193524. Epub 2017 May 4. No abstract available.

29.

Initial Experience With Simultaneous 18F-FDG PET/MRI in the Evaluation of Cardiac Sarcoidosis and Myocarditis.

Hanneman K, Kadoch M, Guo HH, Jamali M, Quon A, Iagaru A, Herfkens R.

Clin Nucl Med. 2017 Jul;42(7):e328-e334. doi: 10.1097/RLU.0000000000001669.

PMID:
28418949
30.

Incidental extra-cardiac findings on 13NH3 myocardial perfusion PET/CT.

Iagaru A.

J Nucl Cardiol. 2017 Dec;24(6):1869-1870. doi: 10.1007/s12350-017-0879-y. Epub 2017 Apr 7. No abstract available.

PMID:
28390040
31.

Dual-Integrin αvβ3- and Gastrin-Releasing Peptide Receptor-Targeting PET Radiotracer (68Ga-BBN-RGD).

Iagaru A.

J Nucl Med. 2017 Oct;58(10):1706. doi: 10.2967/jnumed.117.191478. Epub 2017 Mar 9. No abstract available.

32.

Imaging of Prostate Cancer Using Gallium-68-Labeled Bombesin.

Sonni I, Baratto L, Iagaru A.

PET Clin. 2017 Apr;12(2):159-171. doi: 10.1016/j.cpet.2016.11.003. Epub 2017 Jan 20. Review.

PMID:
28267450
33.

Assessment of skeletal tumour burden on 18F-NaF PET/CT using a new quantitative method.

Lapa P, Marques M, Costa G, Iagaru A, Pedroso de Lima J.

Nucl Med Commun. 2017 Apr;38(4):325-332. doi: 10.1097/MNM.0000000000000654.

PMID:
28230714
34.

Clinical evaluation of TOF versus non-TOF on PET artifacts in simultaneous PET/MR: a dual centre experience.

Ter Voert EEGW, Veit-Haibach P, Ahn S, Wiesinger F, Khalighi MM, Levin CS, Iagaru AH, Zaharchuk G, Huellner M, Delso G.

Eur J Nucl Med Mol Imaging. 2017 Jul;44(7):1223-1233. doi: 10.1007/s00259-017-3619-2. Epub 2017 Jan 26.

PMID:
28124091
35.

Conspicuity of Malignant Lesions on PET/CT and Simultaneous Time-Of-Flight PET/MRI.

Minamimoto R, Iagaru A, Jamali M, Holley D, Barkhodari A, Vasanawala S, Zaharchuk G.

PLoS One. 2017 Jan 19;12(1):e0167262. doi: 10.1371/journal.pone.0167262. eCollection 2017.

36.

Bombesin-Targeted PET of Prostate Cancer.

Mansi R, Minamimoto R, Mäcke H, Iagaru AH.

J Nucl Med. 2016 Oct;57(Suppl 3):67S-72S. Review.

37.

Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer.

Iagaru AH, Mittra E, Colletti PM, Jadvar H.

J Nucl Med. 2016 Oct;57(Suppl 3):19S-24S. Review.

38.

Glioblastoma Multiforme Recurrence: An Exploratory Study of (18)F FPPRGD2 PET/CT.

Iagaru A, Mosci C, Mittra E, Zaharchuk G, Fischbein N, Harsh G, Li G, Nagpal S, Recht L, Gambhir SS.

Radiology. 2016 Jul;280(1):328. doi: 10.1148/radiol.2016164020. No abstract available.

PMID:
27322985
39.

PET Imaging Toward Individualized Management of Urologic and Gynecologic Malignancies.

Sonni I, Iagaru A.

PET Clin. 2016 Jul;11(3):261-72. doi: 10.1016/j.cpet.2016.02.007. Epub 2016 Mar 17. Review.

PMID:
27321030
40.

Editorial Comment.

Iagaru A.

J Urol. 2016 Aug;196(2):390. doi: 10.1016/j.juro.2016.02.2998. Epub 2016 May 17. No abstract available.

PMID:
27207378
41.

Clinical significance of extraskeletal computed tomography findings on 18F-NaF PET/CT performed for osseous metastatic disease evaluation.

Guo HH, Moradi F, Iagaru A.

Nucl Med Commun. 2016 Sep;37(9):975-82. doi: 10.1097/MNM.0000000000000531.

PMID:
27111100
42.

The potential of TOF PET-MRI for reducing artifacts in PET images.

Iagaru A, Minamimoto R, Levin C, Barkhodari A, Jamali M, Holley D, Greg Z.

EJNMMI Phys. 2015 Dec;2(Suppl 1):A77. doi: 10.1186/2197-7364-2-S1-A77. No abstract available.

43.

Imaging patients with breast and prostate cancers using combined 18F NaF/18F FDG and TOF simultaneous PET/ MRI.

Iagaru A, Minamimoto R, Jamali M, Barkodhodari A, Gambhir SS, Vasanawala S.

EJNMMI Phys. 2015 Dec;2(Suppl 1):A65. doi: 10.1186/2197-7364-2-S1-A65. No abstract available.

44.

Whole-body simultaneous time-of-flight PET-MRI: early experience with clinical studies.

Minamimoto R, Iagaru A, Jamali M, Barkodhodari A, Holley D, Vasanawala S, Zaharchuk G.

EJNMMI Phys. 2015 Dec;2(Suppl 1):A64. doi: 10.1186/2197-7364-2-S1-A64. No abstract available.

45.

Dynamic brain PET/MR using TOF reconstruction.

Khalighi MM, Delso G, Tohme M, Iagaru A, Zaharchuk G.

EJNMMI Phys. 2015 Dec;2(Suppl 1):A60. doi: 10.1186/2197-7364-2-S1-A60. No abstract available.

46.

A Prospective, Matched Comparison Study of SUV Measurements From Time-of-Flight Versus Non-Time-of-Flight PET/CT Scanners.

Thompson HM, Minamimoto R, Jamali M, Barkhodari A, von Eyben R, Iagaru A.

Clin Nucl Med. 2016 Jul;41(7):e323-6. doi: 10.1097/RLU.0000000000001170.

PMID:
26914563
47.

Pilot Preclinical and Clinical Evaluation of (4S)-4-(3-[18F]Fluoropropyl)-L-Glutamate (18F-FSPG) for PET/CT Imaging of Intracranial Malignancies.

Mittra ES, Koglin N, Mosci C, Kumar M, Hoehne A, Keu KV, Iagaru AH, Mueller A, Berndt M, Bullich S, Friebe M, Schmitt-Willich H, Gekeler V, Fels LM, Bacher-Stier C, Moon DH, Chin FT, Stephens AW, Dinkelborg LM, Gambhir SS.

PLoS One. 2016 Feb 18;11(2):e0148628. doi: 10.1371/journal.pone.0148628. eCollection 2016.

48.

Improvements in PET Image Quality in Time of Flight (TOF) Simultaneous PET/MRI.

Minamimoto R, Levin C, Jamali M, Holley D, Barkhodari A, Zaharchuk G, Iagaru A.

Mol Imaging Biol. 2016 Oct;18(5):776-81. doi: 10.1007/s11307-016-0939-8.

PMID:
26884058
49.

Spectrum of 68Ga-DOTA TATE Uptake in Patients With Neuroendocrine Tumors.

Moradi F, Jamali M, Barkhodari A, Schneider B, Chin F, Quon A, Mittra ES, Iagaru A.

Clin Nucl Med. 2016 Jun;41(6):e281-7. doi: 10.1097/RLU.0000000000001100.

PMID:
26673240
50.

Pilot Comparison of ⁶⁸Ga-RM2 PET and ⁶⁸Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer.

Minamimoto R, Hancock S, Schneider B, Chin FT, Jamali M, Loening A, Vasanawala S, Gambhir SS, Iagaru A.

J Nucl Med. 2016 Apr;57(4):557-62. doi: 10.2967/jnumed.115.168393. Epub 2015 Dec 10.

Supplemental Content

Loading ...
Support Center